Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | CAMKK2 | Q96RR4 | 15/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CAMKK1 | Q8N5S9 | 11/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567947 | 0.93 | KDM4E (0.47) | PTGDRPTGDR2CAMKK2KDM4EMEN1 | |
| SCHEMBL29235299 | 0.85 | PTGDR (0.50) | PTGDRPTGDR2CAMKK2KDM4EMEN1 | |
| SCHEMBL27172075 | 0.81 | PTGDR (0.50) | PTGDRPTGDR2KDM4EMEN1MAPT | |
| SCHEMBL28170978 | 0.81 | CAMKK2 (0.52) | CAMKK2KDM4ECAMKK1ACMSD | |
| SCHEMBL3443366 | 0.79 | ACMSD (0.53) | CAMKK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL30952631 | 0.79 | KMO (0.54) | CAMKK2CAMKK1ACMSD | |
| SCHEMBL448284 | 0.79 | KMO (0.54) | CAMKK2CAMKK1ACMSD | |
| SCHEMBL23243079 | 0.79 | KDM4E (0.52) | PTGDRPTGDR2KDM4EMEN1MAPT | |
| SCHEMBL18304696 | 0.78 | PTGDR2 (0.57) | PTGDR2CAMKK2CAMKK1ACMSD | |
| SCHEMBL29235196 | 0.77 | PTGDR (0.47) | PTGDRPTGDR2CAMKK2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145607-A1 | Modulators of CAMKK2 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4412999-A1 | MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-25 | — | — | US | disclosed |
| CN-118076603-A | CAMKK2 modulators as ligand-directed degradants | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4337660-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597345-A | Heterocyclic derivatives as CaMKK2 inhibitors | 百时美施贵宝公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023059873-A1 | MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022240826-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| US-7928264-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2011-04-19 | — | — | US | disclosed |
| CN-101039902-B | Aminoalcohol derivatives | ASTELLAS PHARMA INC | 2010-11-10 | — | — | CN | disclosed |
| EP-1593666-B1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080039506-A1 | Aminoalcohol Derivatives | ASTELLAS PHARMA INC. (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-101039902-A | Aminoalcohol derivatives | ASTELLAS PHARMA INC (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1791811-A1 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060128807-A1 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| WO-2006033446-A1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-03-30 | — | — | WO | disclosed |
| CN-1751019-A | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | KISSEI PHARMACEUTICAL (JP) | 2006-03-22 | — | — | CN | disclosed |
| EP-1593666-A1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | CAMKK2, CAMKK1, CAMK1 | PTGDR 869/4885PTGDR2 551/4885CAMKK2 1/4885 |
| US-20250145607-A1 | Modulators of CAMKK2 as Ligand Directed Degraders | CAMKK2, CAMKK1, CAMK1D | PTGDR 1013/4885PTGDR2 719/4885CAMKK2 1/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | PTGDR 188/4885PTGDR2 156/4885CAMKK2 1141/4885 |
| US-20060128807-A1 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | ADRB3, ADRA2C, ADRA1A | PTGDR 277/4885PTGDR2 571/4885CAMKK2 2466/4885 |
| US-20080039506-A1 | Aminoalcohol Derivatives | HRH4, HRH2, CBR3 | PTGDR 71/4885PTGDR2 110/4885CAMKK2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.